Tromethamine
| 證據等級: L5 | 預測適應症: 10 個 |
目錄
Tromethamine: From Metabolic Acidosis to Allergic Urticaria
One-Sentence Summary
Tromethamine (THAM, DrugBank DB03754) is a TRIS-buffer compound whose established clinical role is as a systemic alkalizing agent for metabolic acidosis; no formal indication record or mechanism-of-action data is currently available for this drug itself. The TxGNN model predicts it may be effective for Allergic Urticaria, but this prediction is currently supported by 0 clinical trials and only 1 case-report publication — and that publication actually describes an anaphylactic adverse reaction to a related compound (Ketorolac tromethamine), not a therapeutic benefit. Evidence strength is minimal and the signal should be treated as exploratory only.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not formally recorded in this dataset; known clinical use is as a systemic alkalizing agent for metabolic acidosis |
| Predicted New Indication | Allergic Urticaria |
| TxGNN Prediction Score | 99.91% |
| Evidence Level | L5 |
| US Market Status | Not Marketed |
| Number of NDAs | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism-of-action data is not available for tromethamine itself. Based on known information, tromethamine is a proton-accepting buffer (TRIS) used clinically as a systemic alkalizing agent in metabolic acidosis; it has no established antihistaminic, mast-cell-stabilizing, or immunomodulatory mechanism that would plausibly explain efficacy in allergic urticaria.
The only literature evidence retrieved for this candidate (PMID 16831313) does not actually support the prediction: it is a case report of a biphasic anaphylactic reaction caused by Ketorolac tromethamine, an NSAID that happens to use tromethamine as its salt-forming counter-ion. This is a drug-safety case describing tromethamine’s salt form as a trigger of a hypersensitivity reaction, not evidence that tromethamine treats urticaria. The direction of the association is therefore opposite to what would be needed to support repurposing.
Given the absence of a plausible mechanistic link, the absence of any clinical trial evidence, and a single piece of literature that points toward harm rather than benefit, this TxGNN signal should be interpreted as a graph-based statistical association rather than a clinically meaningful hypothesis at this time.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 16831313 | 2006 | Case Report | Int J Immunopathol Pharmacol | Describes a biphasic anaphylactic reaction following intramuscular Ketorolac tromethamine injection; illustrates a hypersensitivity risk associated with the tromethamine salt form rather than a therapeutic effect on urticaria |
US Market Information
Tromethamine currently has no NDA/license records in this dataset (market status: Not Marketed; total licenses: 0).
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by a TxGNN graph score (L5) with no clinical trials and a single literature item that describes an adverse hypersensitivity reaction rather than therapeutic evidence. Combined with the lack of mechanism-of-action data and the drug’s current non-marketed status, there is no basis to advance this candidate at this time.
To proceed, the following is needed:
- Confirmed mechanism-of-action data for tromethamine (independent of its use as a salt-forming counter-ion in other drugs, e.g., Ketorolac tromethamine, Fosfomycin tromethamol)
- Original approved indication and labeling information (TFDA/FDA label warnings and contraindications — currently a blocking data gap)
- Any pharmacology or preclinical data specifically linking tromethamine (not its salt partners) to mast-cell/histamine pathways relevant to urticaria
- Re-screening of literature/trial evidence to exclude confounding from other tromethamine-salt drugs, which affected several lower-ranked candidates in this same evidence pack (e.g., post-bacterial disorder, post-infectious syndrome) and should be treated as a systematic data-quality caveat for this drug across all predicted indications
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.